Baxter Healthcare Corporation's BioPharma Solutions business offers proprietary technologies and best in class contract services,
addressing outsourcing needs throughout development and commercialization of parenteral (injectable and pulmonary) drugs.
The company has partnered with more than 150 clients, working with the top fifteen bio/pharmaceutical companies.
Baxter is a parenteral market leader providing a range of proven contract services from process development of biopharmaceutical
active ingredients to form–fill–finish of drug product into syringes, vials, and cartridges. Baxter offers the advantage
of providing cytotoxic contract services from chemical synthesis (API) to scale-up for commercial production. With over fifteen
years of experience, we provide contract development and manufacturing services for antibodies and protein therapeutics. Our
licensed facilities in Hayward and Thousand Oaks, California, have capacity for pre-clinical to commercial scale production.
Baxter's Bloomington facility has expanded capacities for syringe and vial filling–finishing; and has added new capability
in cartridge filling–finishing as well as a fully automated kitting line. Lyophilization capacity has increased along with
the establishment of the Lyophilization Center of Excellence. Baxter can also provide analytical and microbiological services
as well as validation and regulatory assistance.
Proprietary Formulation Technologies
NANOEDGE dispersion technology offers innovative formulations for your solubility challenges and is applicable to multiple
routes of administration. It reduces the particle size of most drugs to nanometer size, which can enhance a drug's saturation
solubility and dissolution rate. It also eliminates the need for undesirable cosolvents and can offer higher drug loading
and subsequent lower dose volume.
The PROMAXX microsphere technology is a unique, elegant, and cost effective formulation platform, tailored to fit your specific
requirements. It is applicable to a broad range of molecules — from small molecules and nucleic acids to peptides and proteins.
PROMAXX technology can offer high drug loading and precise particle-size control and enable dosing flexibility across various
administration routes such as injectable and pulmonary with various drug release profiles such as immediate- and sustained-release.
Baxter also offers an extensive portfolio of Ready-To-Use and Ready-To-Mix systems that can help differentiate your molecule
and simplify end-users' drug preparation and administration. An established franchise into critical care clinicians globally
supports end-user acceptance and market presence.
Corporate Relationships Sought
Baxter is actively pursuing and strengthening partnerships including co-development opportunities, out-licensing of internally
developed products, and strategic or full-development programs.
PO Box 3068 927 S. Curry Pike Bloomington, IN 47403
NUMBER OF EMPLOYEES: